{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:17:11Z","timestamp":1788434231478,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.urolonc.2013.09.009","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T21:45:20Z","timestamp":1386452720000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study"],"prefix":"10.1016","volume":"32","author":[{"given":"Goebell","family":"P.J.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcnch","family":"A.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcller","family":"L.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hurtz","family":"H.J.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koska","family":"M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busies","family":"S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marschner","family":"N.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2013.09.009_bib1","unstructured":"Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, Kraywinkel K. u. a. Niere und ableitenden Harnwege. Krebs in Deutschland 2005\/06. H\u00e4ufigkeiten und Trends. Berlin: Robert Koch Institut pp. 80\u20133."},{"key":"10.1016\/j.urolonc.2013.09.009_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1586\/era.10.68","article-title":"Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients","volume":"10","author":"Bellmunt","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2013.09.009_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/bjc.1988.20","article-title":"Who should measure quality of life, the doctor or the patient?","volume":"57","author":"Slevin","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2013.09.009_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6690655","article-title":"Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses","volume":"81","author":"Sneeuw","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2013.09.009_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1464-410X.2009.08972.x","article-title":"u. a. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review","volume":"105","author":"Choueiri","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.09.009_bib6","first-page":"232","article-title":"Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib","volume":"105","author":"Ivanyi","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.urolonc.2013.09.009_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","article-title":"Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma","volume":"36","author":"Schmidinger","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2013.09.009_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.8-suppl_1-5","article-title":"Fatigue and quality of life: lessons from the real world","volume":"8","author":"Flechtner","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2013.09.009_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"u. a. The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.09.009_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.urolonc.2013.09.009_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"Suppl. 4","key":"10.1016\/j.urolonc.2013.09.009_bib12","first-page":"243","article-title":"Treatment of patients with advanced or metastatic renal cell carcinoma (RCC-Registry): a \u201cReal LIFE\u201d treatment overview of non-trial patients in outpatient cancer centres in Germany","volume":"32","author":"M\u00fcller","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.urolonc.2013.09.009_bib13","series-title":"Onkologie","first-page":"52","author":"Nierenzellkarzinom","year":"2010"},{"key":"10.1016\/j.urolonc.2013.09.009_bib14","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdl304","article-title":"An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer","volume":"17","author":"Mathias","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2013.09.009_bib15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2013.09.009_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1781::AID-CNCR4>3.0.CO;2-G","article-title":"A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma","volume":"88","author":"Blazeby","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.09.009_bib17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/bmj.314.7094.1580","article-title":"Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis","volume":"314","author":"Rothwell","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.urolonc.2013.09.009_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00433922","article-title":"Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters","volume":"5","author":"Sigurdard\u00f3ttir","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.urolonc.2013.09.009_bib19","first-page":"709","volume":"38","author":"Sprangers","year":"1999","journal-title":"u. a. Revealing response shift in longitudinal research on fatigue: the use of the thentest approach"},{"key":"10.1016\/j.urolonc.2013.09.009_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0895-4356(92)90052-O","article-title":"The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review","volume":"45","author":"Sprangers","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2013.09.009_bib21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"u. a. Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2013.09.009_bib22","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"u. a. Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 2","key":"10.1016\/j.urolonc.2013.09.009_bib23","first-page":"S41","article-title":"Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects","volume":"1","author":"Kollmannsberger","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2013.09.009_bib24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"u. a. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2013.09.009_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.6004\/jnccn.2007.0090","article-title":"Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes","volume":"5","author":"Borneman","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2013.09.009_bib26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1634\/theoncologist.2009-0048","article-title":"Patient-related barriers to fatigue communication in cancer patients receiving active treatment","volume":"14","author":"Shun","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2013.09.009_bib27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1023\/A:1008318932641","article-title":"Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum","volume":"11","author":"Stone","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2013.09.009_bib28","first-page":"51","article-title":"Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy","volume":"25","author":"Berger","year":"1998","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.urolonc.2013.09.009_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JOP.0822002","article-title":"Effect of pretreatment distress on daily fatigue after chemotherapy for breast cancer","volume":"4","author":"Higgins","year":"2008","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.urolonc.2013.09.009_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0885-3924(99)00082-2","article-title":"Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates","volume":"18","author":"Jacobsen","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.urolonc.2013.09.009_bib31","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/cncr.11253","article-title":"u. a. Fatigue in ovarian carcinoma patients","volume":"97","author":"Holzner","year":"2003","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:47Z","timestamp":1761040847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143913003529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1078143913003529"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.09.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}